Barclays
PRME icon

Barclays’s Prime Medicine PRME Stock Holding History

Barclays’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Sell
63,773
-300,053
-82% -$1.14M ﹤0.01% 3633
2025
Q4 		$1.26M Buy
363,826
+247,926
+214% +$1.1M ﹤0.01% 3276
2025
Q3 		$642K Buy
115,900
+1,098
+1% +$4.46K ﹤0.01% 3641
2025
Q2 		$284K Buy
114,802
+43,378
+61% +$66.9K ﹤0.01% 4075
2025
Q1 		$142K Sell
71,424
-26,197
-27% -$66.8K ﹤0.01% 4257
2024
Q4 		$285K Buy
97,621
+12,924
+15% +$45.4K ﹤0.01% 4140
2024
Q3 		$328K Buy
84,697
+65,593
+343% +$304K ﹤0.01% 4035
2024
Q2 		$98.2K Sell
19,104
-8,486
-31% -$51.4K ﹤0.01% 3917
2024
Q1 		$193K Sell
27,590
-26,645
-49% -$202K ﹤0.01% 4133
2023
Q4 		$481K Sell
54,235
-10,905
-17% -$84K ﹤0.01% 3901
2023
Q3 		$621K Buy
65,140
+57,261
+727% +$744K ﹤0.01% 2666
2023
Q2 		$115K Buy
7,879
+2,543
+48% +$35.5K ﹤0.01% 3504
2023
Q1 		$65.6K Buy
5,336
+2,549
+91% +$41.5K ﹤0.01% 4356
2022
Q4 		$51.8K Buy
+2,787
New +$50.3K ﹤0.01% 4539

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Barclays's PRME Position: Q1 2026 in Review

Barclays reduced its Prime Medicine (PRME) stake by 82% in Q1 2026, selling an estimated $1.14M and leaving 63,773 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3633.

Barclays first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.26M in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Barclays held 63,773 shares of Prime Medicine worth $222K as of Q1 2026.
  • Barclays sold 300,053 Prime Medicine shares in Q1 2026, an estimated $1.14M.
  • Prime Medicine made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3633 holding.
  • Barclays first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Barclays's Prime Medicine position peaked at $1.26M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.